Aducanumab for Alzheimer's Disease: The Never-ending Story That Nurses Should Know

Overview

Journal Nurs Open

Specialty Nursing

Date 2021 Apr 7

PMID 33825339

Citations 3

Authors

Joel Petch

Daniel Bressington

Affiliations

Soon will be listed here.

Citing Articles

Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer's Disease.

Li J, Haj Ebrahimi A, Ali A Int J Mol Sci. 2024; 25(10).

PMID: 38791206 PMC: 11121252. DOI: 10.3390/ijms25105169.

Avoiding future controversies in the Alzheimer's disease space through understanding the aducanumab data and FDA review.

Dickson S, Hennessey S, Nicodemus Johnson J, Knowlton N, Hendrix S Alzheimers Res Ther. 2023; 15(1):98.

PMID: 37226162 PMC: 10207692. DOI: 10.1186/s13195-023-01238-1.

Aducanumab for Alzheimer's disease: The never-ending story that nurses should know.

Petch J, Bressington D Nurs Open. 2021; 8(4):1524-1526.

PMID: 33825339 PMC: 8186671. DOI: 10.1002/nop2.878.

References

Wang C, Holtzman D . Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. Neuropsychopharmacology. 2019; 45(1):104-120. PMC: 6879647. DOI: 10.1038/s41386-019-0478-5. View

Ackley S, Zimmerman S, Brenowitz W, Tchetgen Tchetgen E, Gold A, Manly J . Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021; 372:n156. PMC: 7905687. DOI: 10.1136/bmj.n156. View

Petch J, Bressington D . Aducanumab for Alzheimer's disease: The never-ending story that nurses should know. Nurs Open. 2021; 8(4):1524-1526. PMC: 8186671. DOI: 10.1002/nop2.878. View